DOI: 10.7759/cureus.53111

Review began 11/13/2023 Review ended 01/23/2024 Published 01/28/2024

source are credited.

© Copyright 2024
Abdulfattah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and

Awareness of Non-alcoholic Fatty Liver Disease and Its Determinants in Jazan, Saudi Arabia: A Cross-Sectional Study

Alfadl A. Abdulfattah 1 , Erwa Eltayib. Elmakki 1 , Bushra I. Maashi 2 , Bushra A. Alfaifi 2 , Asmaa S. Almalki 3 , Njoud AL Alhadi 2 , Hamad Majrabi 4 , Abdulrahman Kulaybi 2 , Ayoub Salami 4 , Fouad I. Hakami 2

1. Internal Medicine, Jazan University, Jazan, SAU 2. College of Medicine, Jazan University, Jazan, SAU 3. Clinical Nutrition, Jazan University, Jazan, SAU 4. Emergency Department, King Fahad Central Hospital, Jazan, SAU

Corresponding author: Ayoub Salami, dr.ayooub@gmail.com

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis. It is the leading cause of liver-related mortality, end-stage liver disease, and the need for liver transplantation. This study aimed to assess the level of awareness regarding NAFLD among the adult population in Jazan, Saudi Arabia, and to explore the determinants of the awareness level.

Method

This descriptive cross-sectional study was conducted among the general population of Jazan, Saudi Arabia, under the supervision of Jazan University, excluding those with end-stage liver failure. An online self-administered questionnaire, adopted from the literature, was sent through different social media platforms. A total of 1,034 people participated in this study. The chi-square test and multiple linear regression were used to identify the predictors of NAFLD awareness.

Results

Fifty-three percent of the participants were aware of NAFLD. The mean score of the participants' awareness was 22.7 ± 4.9 out of 40 points. Employed (95% confidence interval (CI): -1.9, -0.03; p = 0.044) and private business individuals (95% CI: -3.5, -1.1; p < 0.001) had a lower awareness level than students. The higher income level was associated with greater awareness (95% CI: 0.36, 2.4; p = 0.008). Those who had never heard of NAFLD had nearly twice as much awareness (95% CI: -3.0, -0.67; p = 0.002).

Conclusions

Nearly half the study participants displayed good awareness of NAFLD. However, efforts must focus on awareness campaigns, encouraging health-seeking behaviors, and targeted screening for early detection and treatment, especially in at-risk populations, since many participants were unaware of NAFLD.

Categories: Family/General Practice, Gastroenterology, Internal Medicine Keywords: jazan, awareness, middle east, liver disease, nafld

Introduction

Non-alcoholic fatty liver disease (NAFLD) represents a complex spectrum of liver disorders characterized by hepatic steatosis and excessive fat accumulation within the liver without secondary causes, such as heavy alcohol consumption. This spectrum ranges from non-alcoholic fatty liver (NAFL), which tends to be relatively benign, to a more severe and potentially progressive form known as non-alcoholic steatohepatitis (NASH). Left unaddressed, NAFLD can lead to fibrosis and cirrhosis, which pose significant threats to public health [1,2].

NAFLD is distinctly categorized into two types. The first type is closely associated with metabolic syndrome. The prevailing understanding implicates insulin resistance as the primary underlying mechanism [3-5]. Individuals with NAFLD often exhibit one or more components of metabolic syndrome, such as systemic hypertension, dyslipidemia, insulin resistance, or overt diabetes [6].

NAFLD has surged globally, affecting approximately 30.05% of the world's population [7]. It is the leading cause of liver-related mortality [8] and end-stage liver disease [9], often necessitating liver transplantation [10]. Escalating epidemics of obesity and type-2 diabetes mellitus have fueled the rise in NAFLD [11,12]. The Middle East has witnessed a notable increase in NAFLD prevalence in recent years, from 36.53% in 1990 to 42.62% in 2019 [7]. A systematic review reported an NAFLD prevalence of 16.8% in Saudi Arabia [13]. In

particular, the obesity rates in Saudi Arabia exceed the global average, contributing to a higher prevalence of NAFLD in the region [14].

Despite the growing global significance of NAFLD, awareness of this condition remains dismally low. In the United States, NAFLD awareness is only 4.4%, representing a glaring discrepancy compared to the awareness levels of other liver-related disorders, such as viral hepatitis [15]. European countries exhibited similarly low awareness rates [16]. One study found that only 2.4% of the individuals diagnosed with NAFLD were aware of their condition [17].

However, the importance of raising awareness of NAFLD cannot be overstated. Elevated awareness is a pivotal step toward increasing treatment uptake, facilitating informed decisions, and promoting crucial behavioral changes, such as lifestyle modifications. Beyond its clinical implications, NAFLD has a significant economic impact and diminishes the overall health-related quality of life of affected individuals [18].

This study aimed to assess the level of NAFLD awareness among the adult population in Jazan, Saudi Arabia, and to identify the factors influencing this awareness.

Materials And Methods

This study represents a descriptive cross-sectional investigation undertaken within the geographic confines of the Jazan region, situated in the southwestern expanse of Saudi Arabia, contiguous with the Red Sea, encompassing an approximate population of 1.5 million residents. The study included the population of Jazan aged 18 years or above who possessed basic literacy skills and had social media platforms. Individuals with end-stage liver failure were excluded.

The sample size was determined using the following formula:

$$n = z^2 p(1-p)/d^2$$
,

where Z corresponds to a 95% confidence level, p denotes the anticipated population proportion, and d denotes the 5% margin of error. In addition, a 10% nonresponse rate was factored in, yielding a minimum sample size of 440 participants.

Data collection

A preliminary pilot study involving a selected group of participants was conducted to assess the questionnaire's clarity and understanding. Participant feedback from the preliminary phase was incorporated into the final survey. The survey tool was disseminated to participants through Google Forms, Facebook, and WhatsApp, employing convenience sampling.

The questionnaire comprised two principal sections. The first segment collected demographic data, including age, gender, nationality, employment status, educational qualifications, and monthly income. The second section featured the validated questionnaire derived from previous studies [19] that explored the participants' NAFLD knowledge, including prior liver disease diagnoses among respondents or their close relatives. Moreover, it delved into the participants' awareness of NAFLD, including their comprehension of the risk factors, diagnostic methodologies, treatment modalities, associated symptoms, and potential complications arising from this condition. Furthermore, the participants' perceptions toward NAFLD curability, preventability, and potentially life-threatening effects were assessed.

A structured scoring system was implemented to assess NAFLD awareness. Correct, incorrect, and neutral responses were assigned scores of 2, 0, and 1, respectively. Subsequently, a cumulative awareness score was computed for each participant, resulting in scores ranging from 0 to 40 points. Higher scores indicated greater levels of awareness.

The normality of the data distribution was examined using the Kolmogorov-Smirnov test. To categorize awareness data, the median score was employed as a delineating threshold, bifurcating participants into those classified as "aware" (those scoring greater than or equal to the median) and those designated as "not aware" (those scoring less than the median). Categorical data were presented using frequency and percentage. To identify the factors associated with NAFLD awareness, multiple linear regression analysis was performed. The statistical significance of the study was set at p < 0.05.

Ethical considerations

Ethical approval was obtained from the Jazan Health Ethics Committee (IRB No.: REC-44/05/404). Each participant was provided with a comprehensive explanation of the study's objectives. Written informed consent was obtained from all participants, affirming their voluntary participation in the study. The ethical preference for participant withdrawal at any point was emphasized. The anonymity and confidentiality of participants' identities and responses were maintained.

Results

In this study, 1,034 participants were enrolled, primarily within the 18-24-year age group (48.5%). Most participants were female (72.9%), of Saudi nationality (96.7%), and possessed a bachelor's degree (61.1%). The predominant occupational category was students (38.4%), with the majority reporting a monthly income below 5000 Saudi Riyals (58.7%). Notably, a substantial proportion of participants (62.3%) indicated no prior awareness of NAFLD, with 14.3% reporting educational curricula as their primary source of information on NAFLD (Table 1).

characteristic	n	(%)
ge (years)		
8-24	502	48.5%
5-34	283	27.4%
5-44	162	15.7%
5-54	69	6.7%
5-64	15	1.5%
5 and above	3	0.3%
Sender		
remale	754	72.9%
fale	280	27.1%
lationality		
lon-Saudi	34	3.3%
audi	1,000	96.7%
evel of education		
rimary	6	0.6%
ntermediate	25	2.4%
secondary	232	22.4%
achelor's	632	61.1%
Others	139	13.4%
Occupation		
imployed	239	23.1%
rrivate business	79	7.6%
lousewife	116	11.2%
student	397	38.4%
tetired	203	19.6%
ncome level		
ess than 5000 SR	607	58.7%
000-10,000 SR	222	21.5%
0,000-15,000 SR	135	13.1%
fore than 15,000 SR	70	6.8%
ource of information		
riends/relatives	55	5.3%

From my doctor	31	3%	
Social media	99	9.6%	
Others	57	5.5%	
I have never heard about it before	644	62.3%	

TABLE 1: Sociodemographic characteristics of the study participants

SR: Saudi Riyals

It was ascertained that 9.4% of the participants had either a personal diagnosis of NAFLD or were acquainted with it through a relative's diagnosis. Notably, 77% of the respondents acknowledged NAFLD's potential to induce hepatic inflammation, whereas 50% were ignorant regarding its presenting symptoms. In addition, 47% identified obesity as a prevalent risk factor, with 39% recognizing end-stage liver disease as a potential complication. Of the participants, 42% perceived NAFLD as preventable, 50% believed it was curable, and 53% considered it a life-threatening condition (Table 2).

aracteristic	N = 1,034 ¹
ve you or someone you know ever been diagnosed with NAFLD?	
rs*	97 (9.4%)
	732 (71%)
lon't remember	205 (20%)
AFLD is characterized by the accumulation of	
ats in heart	8 (0.8%)
ats in the liver*	639 (62%)
lon't know	359 (35%)
In liver	28 (2.7%)
o you think NAFLD can only occur if it runs in the family?	
gree	174 (17%)
sagree*	352 (34%)
don't know	508 (49%)
o you think healthy eating habits can prevent NAFLD?	
gree*	708 (68%)
sagree	76 (7.4%)
don't know	250 (24%)
eople with low blood pressure are at higher risk of NAFLD.	
gree	244 (24%)
isagree*	151 (15%)
don't know	639 (62%)
iabetes is related to NAFLD	
gree*	362 (35%)
sagree	131 (13%)
lon't know	541 (52%)

	Agree	291 (28%)
The state of the SET Defends of	Disagree*	208 (20%)
The state of the SET Defends of		
10 10 10 10 10 10 10 10		
1 11 11 11 11 11 11 11 11 11 11 11 11 1		70 (6.8%)
e* 1 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1		
Statistical State and comments of proportion (APPT (27)) 4 (17) (27) (27) (27) (27) (27) (27) (27) (2		
With the manifolianger of MATICE 4 (1) Fright manifolianger 4 (2) Maticals 4 (2) Matter 4 (2)		
Part part of the thorage of		0.1,00%)
Meaded Name \$1,250 Name and starting 1 \$2,500 With Interface on stagents to depose \$1,000 to depos		104 (10%)
Received wordshifting 20 pc. 20		
150 150		
With Interface are helded for decess to disgrate MAFLE? 60 6 1 5 0 Bike 45 6 4 5 0 Bike 45 6 1 5 0 Interface for the park 47 6 6 0 Correct for park 47 6 7 0 Correct for park 47 6 7 0 Mark 47 6 7 0 Add to late. 47 6 7 0 Mark 47 6 7 0 Add to late. 47 6 7 0 Mark 47 6 7 0 Add to late. 47 6 7 0 Mark 47 6 7 0 Add to late. 47 6 7 0 Mark 47 6 7 0 Add to late. 47 6 7 0 Mark 47 6 7 0 Add to late. 47 6 7 0 </td <td></td> <td></td>		
Bits of basis \$ (4 kg) Bits		519 (50%)
Bits 45 (4%) Integrate Societies 45 (4%) Act of Locals* 45 (4%) Identify More 45 (4%) More Integrated Producted For definite despress of MAPLD? 75 (4%) CT 75 (4%) Mark 45 (4%) Mark 45 (4%) More Season? 45 (4%) More Interested on Annual Societies Producted of Annual Societies Producted Office Annual		
1		
Al of these'* 47 (48%) 1 don't know 36 (48%) What is the standard method for definite dispracis of NAFLD? CT 70 (8.8%) MER 75 (3.8%) MER 75 (3.8%) 1 don't know 37 (4.8%) 1 don't know 38 (4.8%	BMI	
1 don't troox 355 (24%) What is the standard method for definite disgrosis of NAFLD? 70 (8.8%) CT 70 (8.8%) Liver boppy* 300 (22%) MR 75 (7.3%) USG 47 (4.5%) It don't know 912 (55%) What is the standard method for definite breatment of NAFLD? 57 (17%) Laparoscopy 917 (15%) Surgical intervention 157 (15%) None* 61 (7.9%) I definit know 160 (9.8%) NAFLD con causes in the here 175 (77%) Vibrage 41 (33%) Seeling 46 (87%) What can be the associated complications of NAFLD? 150 (10%) Tril delays four disease* 160 (10%) End desire* 46 (87%) Best Intervention 46 (87%)	Imaging techniques	94 (9.1%)
What is the standard method for definite diagnosis of NAFLD? 70 (8 8%) CT 70 (8 8%) Liber biopsy* 30 (23%) USG 47 (45%) USG 47 (45%) USG 47 (45%) USG 50 (45%) What is the standard method for definite treatment of NAFLD? 50 (45%) What is the standard method for definite treatment of NAFLD? 50 (45%) Liberancescy 50 (45%) Singular intervention 47 (75%) Nores* 150 (50%) 150 (51) Intoin 61 (60%) NAFLD can cause in the four 75 (77%) Influencescory 51 (67%) Swelling 51 (67%) What can be the associated complications of NAFLD? 51 (77%) User cannot " 50 (10%) Enrichage four disease" 50 (10%) User cannot " 40 (10%)	All of these*	477 (46%)
CT 70 (88%) Live bispay* 300 (28%) MR 70 (81%) USG 47 (81%) It don't from 47 (81%) It don't from 50 (48%) It don't from the best-dard method for defends treatment of MAPLD? 70 (18%) Responsibility 40 (81%) Supposite informention 47 (18%) Responsibility 10 (81%) Information* 40 (80%) Information* 70 (77%) Information* 70 (77%) Information* 40 (87%) What can be the associated complications of NAPLD? 11 (33%) User cancies* 10 (18%) End slipp Nov desease* 40 (80%) Birth Innov 40 (80%)	I don't know	355 (34%)
Note this page 19 19 19 19 19 19 19 1	What is the standard method for definite diagnosis of NAFLD?	
NR 75 (7.3%) USG 47 (4.5%) I don't brow 512 (5%) What is the standard methods for definite breatment of NAFLD? ************************************	СТ	70 (6.8%)
USG 47 (45%) I don't forow 512 (50%) What is the standard method for definite treatment of NAFLD? 50 (48%) Laparoscopy 50 (48%) None* 51 (75%) None* 61 (78%) I don't know 919 (80%) NAFLD can cause in the liver 785 (77%) Inflammation* 785 (77%) What can be the associated complications of NAFLD? 41 (30%) End stappe liver disease* 406 (80%) Brill tumpr 15 (15%)	Liver biopsy*	330 (32%)
Ident know What is the standard method for definite treatment of NAFLD7 Angoplasty Angoplasty Surgical intervention Angoplasty None* None	MR	75 (7.3%)
What is the standard method for definite treatment of NAFLD? 50 (4.5%) Angioplassy 50 (4.5%) Laparoscopy 157 (15%) Surgical intervention 157 (15%) None* 61 (7.6%) I don't know 619 (80%) NAFLD can cause in the liver 756 (77%) Inflammation* 765 (77%) Swelling 661 (67%) What can be the associated complications of NAFLD? 106 (10%) End-stage liver disease* 466 (89%) Brain tumor 15 (1.5%)	use	47 (4.5%)
Angioplasty Angioplasty Laparoscopy Surgical intervention Surgical	I don't know	512 (50%)
Laparoscopy 127 (12%) Surgical Intervention 157 (15%) None* 81 (7.8%) I don't know 619 (60%) NAFLD can cause in the liver 795 (77%) Inflammation* 91 (67%) Swelling 91 (67%) What can be the associated complications of NAFLD? 106 (10%) End-stage liver disease* 406 (39%) Brain tumor 15 (1.5%)	What is the standard method for definite treatment of NAFLD?	
Surgical intervention 157 (15%) None* None* None* NAFLD can cause in the liver Inflammation* Injury National of MAFLD? What can be the associated complications of NAFLD? Liver cancer* Liver cancer* Bright disease* Bright tumor A 157 (15%) 157 (15%)	Angioplasty	50 (4.8%)
None* I don't know 619 (60%) NAFLD can cause in the liver Inflammation* 795 (77%) Injury 411 (33%) Swelling 691 (67%) What can be the associated complications of NAFLD? Liver cancer* 106 (10%) End-stage liver disease* 406 (39%) Brain tumor 15 (1.5%)	Laparoscopy	127 (12%)
I don't know NAFLD can cause in the liver Inflammation* Swelling What can be the associated complications of NAFLD? Liver cancer* End-stage liver disease* Brain tumor 619 (60%) 619 (60%) 795 (77%)	Surgical intervention	157 (15%)
NAFLD can cause in the liver Inflammation* 795 (77%) Injury 341 (33%) Swelling What can be the associated complications of NAFLD? Liver cancer* 106 (10%) End-stage liver disease* 15 (1.5%)	None*	81 (7.8%)
Inflammation* 795 (77%) Injury 341 (33%) Swelling 691 (67%) What can be the associated complications of NAFLD? Liver cancer* 106 (10%) End-stage liver disease* 406 (39%)	I don't know	619 (60%)
Injury Swelling What can be the associated complications of NAFLD? Liver cancer* End-stage liver disease* 106 (10%) Brain tumor 15 (1.5%)	NAFLD can cause in the liver	
Swelling What can be the associated complications of NAFLD? Liver cancer* End-stage liver disease* 106 (10%) Brain tumor 15 (1.5%)	Inflammation*	795 (77%)
What can be the associated complications of NAFLD? Liver cancer* End-stage liver disease* 106 (10%) 406 (39%) Brain tumor 15 (1.5%)	Injury	341 (33%)
Liver cancer* 106 (10%) End-stage liver disease* 406 (39%) Brain tumor 15 (1.5%)	Swelling	691 (67%)
End-stage liver disease* 406 (39%) Brain tumor 15 (1.5%)	What can be the associated complications of NAFLD?	
Brain tumor 15 (1.5%)	Liver cancer*	106 (10%)
	End-stage liver disease*	406 (39%)
Cardiovascular disease 73.77 1%	Brain tumor	15 (1.5%)
	Cardiovascular disease	73 (7.1%)

Skeletal dysfunction	12 (1.2%)
don't know	422 (41%)
What are the common risk factors associated with NAFLD?	
Obesity*	483 (47%)
Metabolic disorders*	416 (40%)
Diabetes mellitus*	316 (31%)
Parkinson's disease	111 (11%)
Dermatitis	117 (11%)
don't know	460 (44%)
Do you think NAFLD can be prevented?	
Yes*	431 (42%)
No	94 (9.1%)
l don't know	509 (49%)
Do you think NAFLD can be cured?	
Yes*	521 (50%)
No	85 (8.2%)
Idon't know	428 (41%)
Can NAFLD be life-threatening?	
Yes*	551 (53%)
No	72 (7.0%)
Idon't know	411 (40%)
¹ n (%), *correct answer	

TABLE 2: Awareness regarding NAFLD among the adult population of Jazan

NAFLD: non-alcoholic fatty liver disease, BMI: body mass index, CT: computed tomography, MR: magnetic resonance, USG: ultrasound sonography

The mean awareness score was 22.7 ± 4.9 out of a maximum attainable score of 40, with a median score of 22. Notably, 52.9% of the participants were categorized as "aware" of NAFLD, while 47.1% fell into the "not aware" category (Figure 1).




FIGURE 1: Awareness level of NAFLD among the adult population of Jazan

Distinct patterns emerged when assessing the determinants of NAFLD awareness among the study participants. Employed individuals exhibited a 0.97-point decrease in awareness levels compared to students (95% CI: -1.9, -0.03, p = 0.044), while participants engaged in private business demonstrated a substantially greater decrement, with a 2.3-fold reduction in awareness compared to students (95% CI: -3.5, -1.1; p < 0.001). Furthermore, participants within the income bracket of 10,000-15,000 Saudi Riyals exhibited 1.4 times higher awareness than those with incomes below 5,000 Saudi Riyals (95% CI:0.36, 2.4; p = 0.008). Notably, participants with no prior exposure to information about NAFLD were found to possess nearly half the level of awareness as those who had received information from friends or relatives (95% CI: -3.0, -0.67; p = 0.002) (Table 3).

Characteristic	Beta	95% CI ¹	p value
		55 /6 GI	
Nationality			
Non-Saudi	-	_	
Saudi	1.1	-0.57, 2.7	0.2
Occupation			
Student	-	-	
Employed	-0.97	-1.9, -0.03	0.044
Housewife	-0.20	-1.1, 0.74	0.7
Private business	-2.3	-3.5, -1.1	<0.001
Retired	-0.72	-1.5, 0.10	0.086
Income level			
Less than 5000 SR	-	-	
5000-10,000 SR	0.11	-0.72, 0.94	0.8
10,000-15,000 SR	1.4	0.36, 2.4	0.008
More than 15,000 SR	0.21	-0.99, 1.4	0.7
Source of information			
Friends/relatives	-	_	
I have not heard about it before	-1.8	-3.0, -0.67	0.002
Social media	-0.77	-2.2, 0.63	0.3
Others	0.00	-1.9, 1.9	>0.9

TABLE 3: Predictors of NAFLD awareness among the adult population of Jazan

¹CI: confidence interval; SR: Saudi Riyals; NAFLD: non-alcoholic fatty liver disease

Being Saudi or a student and having a bachelor's degree was associated with higher NAFLD awareness (p < 0.05). An income of less than 5000 Saudi riyals was associated with higher NAFLD awareness (p < 0.05) (Table 4).

	Awareness level		
Characteristic	Aware, N = 547 ¹	Not aware, N = 487 ¹	p value ²
Gender			0.089
Female	411 (75%)	343 (70%)	
Male	136 (25%)	144 (30%)	
Age (years)			0.2
18-24	278 (51%)	224 (46%)	
25-34	148 (27%)	135 (28%)	
35-44	82 (15%)	80 (16%)	
45-54	28 (5.1%)	41 (8.4%)	
55-64	10 (1.8%)	5 (1.0%)	
65 and above	1 (0.2%)	2 (0.4%)	

Nationality			0.005
Non-Saudi	10 (1.8%)	24 (4.9%)	
Saudi	537 (98%)	463 (95%)	
Level of education			<0.001
Primary	1 (0.2%)	5 (1.0%)	
Intermediate	11 (2.0%)	14 (2.9%)	
Secondary	100 (18%)	132 (27%)	
Bachelors	380 (69%)	252 (52%)	
Others	55 (10%)	84 (17%)	
Occupation			<0.001
Employed	126 (23%)	113 (23%)	
Housewife	59 (11%)	57 (12%)	
Private business	30 (5.5%)	49 (10%)	
Student	239 (44%)	158 (32%)	
Retired	93 (17%)	110 (23%)	
Income level			0.024
Less than 5000 SR	328 (60%)	279 (57%)	
5000-10,000 SR	101 (18%)	121 (25%)	
10,000-15,000 SR	83 (15%)	52 (11%)	
More than 15,000 SR	35 (6.4%)	35 (7.2%)	
Source of information			<0.001
From my curriculum	128 (23%)	20 (4.1%)	
Friends/relatives	30 (5.5%)	25 (5.1%)	
I have not heard about it before	282 (52%)	362 (74%)	
Others	54 (9.9%)	34 (7.0%)	
Social media	53 (9.7%)	46 (9.4%)	

TABLE 4: Relationship between the participants' sociodemographic characteristics and their awareness level

¹n (%); ²Pearson's chi-squared test; Fisher's exact test; SR: Saudi Riyals

Discussion

NAFLD is a common benign liver disease. However, it can progress to fibrosis in approximately 32% of cases and to cirrhosis in 20% of cases, over a 10-year course [20]. Despite the high prevalence of NAFLD in Saudi Arabia, studies on the awareness of this disease among the general population are few.

Therefore, the current study aimed to assess the awareness of NAFLD among the population of Jazan. Employed and private business workers were significantly more aware of NAFLD than those who belonged to other occupations (p = 0.044 and 0.001, respectively).

There was a significant correlation between the awareness level and Saudi nationality (p = 0.005). This could be attributed to the high socioeconomic levels and educational privileges among the original Saudi residents compared to non-Saudis who are mostly marginalized or illiterate workers.

The sources of information for most participants were their curriculum (14.3%) and social media (9.6%), which are similar to those of a study on Mexican women where their information sources on NAFLD were mostly family and media [21].

In the present study, 53% of the respondents were aware of NAFLD. By contrast, a similar study by Aljahdli et al. in 2021 on the Saudi population in Jeddah reported an overall awareness of 33% among the study participants [22]. This difference could be attributed to differences between the study samples, improvements in health education programs, and the growing use of smartphones and social communication platforms in Saudi Arabia.

In the current study, 71% of the participants reported that they or their relatives had never been diagnosed with NAFLD, and approximately 48% had a low level of awareness about the disease. Another Asian community-based study conducted in 2020 in Singapore revealed that 71.2% of the participants had heard about NAFLD; a more recent study reported awareness at 75% [23,24].

Despite both being Asian countries and developed economies, the Singaporean population had a better awareness of NAFLD than the Saudi population. Both communities appreciate the fact that NAFLD can be dangerous and life-threatening (53% in Saudi Arabia and 68.8% in Singapore) [23].

Nevertheless, most of our study participants indicated that the disease could be prevented (42%) and cured (50%), compared with 2% and 1%, respectively, in the Brooklyn population [20]. When asked about the familial nature of the disease, 17% of our participants agreed that NAFLD runs in the family, compared to 70% of the United States population who indicated that it is hereditary. A study from a different continent concluded that approximately 84% of the United States population was unaware of NAFLD and the conditions that could predispose them to it. When asked about the risk factors for NAFLD, 44% of our participants indicated their ignorance, compared to 83% of the Brooklyn-USA residents [20]. Interestingly, 49% of the South Korean population was aware of NAFLD, and less than half were aware of its risk factors [25].

Limitations and strengths of the current study

The present study provides significant findings regarding the awareness of NAFLD and its risk factors among people in the Jazan region of Saudi Arabia. However, it also has some limitations. One of the main drawbacks of this study is the use of an online self-administered questionnaire, which may result in a high frequency of missed data and inaccurate answers compared to an interview-based questionnaire. Moreover, only those with good Internet access could have been included in this study. Second, most study respondents and participants were young students, causing an indirect selection bias that could have affected the conclusion. We hope that these limitations will be addressed in future survey-based observational studies.

The strengths of this study include the use of a validated Arabic-translated questionnaire. Furthermore, the sample was adequate and representative of the entire population and the results and conclusions represent an excellent addition to the medical literature. Finally, the present study will undoubtedly enrich the epidemiological data regarding the awareness of NAFLD and its risk factors among the Saudi population.

Recommendations

Based on the outcomes of this study, we recommend strategic planning of awareness campaigns about NAFLD among residents of Jazan and other Saudi areas, in addition to conducting more nationwide surveys to establish awareness levels among the Saudi population and assess their health-seeking behaviors.

Conclusions

More than half of the study participants have good knowledge about NAFLD, yet around 47.1% have low awareness levels, which necessitate establishing awareness programs and enhancing health-seeking behaviors in addition to screening at-risk populations for early diagnosis and treatment of this prevalent disease. The predictors of awareness among our participants were private businesses and high income level. There were no differences in the awareness level between males and females and between the different age groups. Nevertheless, there was a statistically significant difference in awareness level according to nationality, educational level, occupation, and level of income.

Additional Information

Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work

Concept and design: Bushra I. Maashi, Abdulrahman Kulaybi, Njoud AL Alhadi , Asmaa S. Almalki, Hamad Majrabi , Bushra A. Alfaifi, Alfadl A. Abdulfattah, Erwa Eltayib. Elmakki, Ayoub Salami, Fouad I. Hakami

Acquisition, analysis, or interpretation of data: Bushra I. Maashi, Abdulrahman Kulaybi, Njoud AL Alhadi, Asmaa S. Almalki, Hamad Majrabi, Bushra A. Alfaifi, Alfadl A. Abdulfattah, Erwa Eltayib. Elmakki, Ayoub Salami, Fouad I. Hakami

Drafting of the manuscript: Bushra I. Maashi, Abdulrahman Kulaybi, Njoud AL Alhadi , Asmaa S. Almalki, Hamad Majrabi , Bushra A. Alfaifi, Alfadl A. Abdulfattah, Erwa Eltayib. Elmakki, Ayoub Salami, Fouad I. Hakami

Critical review of the manuscript for important intellectual content: Bushra I. Maashi, Abdulrahman Kulaybi, Njoud AL Alhadi , Asmaa S. Almalki, Hamad Majrabi , Bushra A. Alfaifi, Alfadl A. Abdulfattah, Erwa Eltayib. Elmakki, Ayoub Salami, Fouad I. Hakami

Supervision: Alfadl A. Abdulfattah, Erwa Eltayib. Elmakki

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Jazan Health Ethics Committee issued approval IRB No.: REC-44/05/404. Each participant was provided with a comprehensive explanation of the study's objectives. Written informed consent was obtained from all participants, affirming their voluntary participation in the study. The ethical preference for participant withdrawal at any point was emphasized. The anonymity and confidentiality of participants' identities and responses were maintained. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We would like to extend our gratitude to the Station of Medical Essentials (SOME) Institution for their invaluable contribution in analyzing the data presented in this study.

References

- Ahmed A, Wong RJ, Harrison SA: Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015, 13:2062-70. 10.1016/j.cgh.2015.07.029
- Machado MV, Diehl AM: Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016, 150:1769-77. 10.1053/j.gastro.2016.02.066
- Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001, 21:27-41. 10.1055/s-2001-12927
- Fromenty B, Pessayre D: Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol. 1997, 26:43-53. 10.1016/s0168-8278(97)80496-5
- Pouwels S, Sakran N, Graham Y, et al.: Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186/s12902-022-00980-1
- Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001, 121:91-100. 10.1053/gast.2001.25540
- Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L: The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097/HEP.0000000000000004
- Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM: Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020, 72:1605-16. 10.1002/hep.31173
- Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ: Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018, 67:123-33. 10.1002/hep.29466
- Wong RJ, Cheung R, Ahmed A: Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014, 59:2188-95. 10.1002/hep.26986
- $11. \quad Lin X, Xu Y, Pan X, et al.: Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020, 10:14790. 10.1038/s41598-020-71908-9$
- Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM: Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018, 97:e0214. 10.1097/MD.000000000010214
- Salem V, AlHusseini N, Abdul Razack HI, Naoum A, Sims OT, Alqahtani SA: Prevalence, risk factors, and interventions for obesity in Saudi Arabia: a systematic review. Obes Rev. 2022, 23:e13448.
 10.1111/obr.13448
- Alenezi YM, Harris R, Morling J, Card T: Prevalence of non-alcoholic fatty liver disease (NAFLD) in Saudi Arabia: systematic review and meta-analysis. Cureus. 2023, 15:e40308. 10.7759/cureus.40308

- Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM: Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun. 2021, 5:1833-47. 10.1002/hep4.1765
- Lazarus JV, Ekstedt M, Marchesini G, et al.: A cross-sectional study of the public health response to nonalcoholic fatty liver disease in Europe. J Hepatol. 2020, 72:14-24. 10.1016/j.jhep.2019.08.027
- Cleveland ER, Ning H, Vos MB, et al.: Low awareness of nonalcoholic fatty liver disease in a populationbased cohort sample: the CARDIA study. J Gen Intern Med. 2019, 34:2772-8. 10.1007/s11606-019-05340-9
- 18. Younossi ZM, Henry L, Bush H, Mishra A: Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2018, 22:1-10. 10.1016/j.cld.2017.08.001
- Alsubaie A, Mohammad S, Alqarni A, et al.: Awareness of adult population toward non-alcoholic fatty liver disease in Riyadh, Saudi Arabia. Int J Dev Ctries. 2020, 1938:44. 10.24911/IJMDC.51-1602163627
- Ghevariya V, Sandar N, Patel K, Ghevariya N, Shah R, Aron J, Anand S: Knowing what's out there: awareness
 of non-alcoholic fatty liver disease. Front Med (Lausanne). 2014, 1:4. 10.3389/fmed.2014.00004
- Morrill KE, Crocker RM, Hingle MD, Thomson CA, Garcia DO: Awareness, knowledge, and misperceptions
 related to nonalcoholic fatty liver disease in a community sample of Mexican-origin women: a mixed
 methods study. Front Public Health. 2021, 9: 10.3389/fpubh.2021.626428
- Aljahdli ES , Fallatah HI , Alharbi AS , Alwagdani S, Makin M: Awareness of non-alcoholic fatty liver disease is low in the general population of Saudi Arabia. Int J Med Dev Ctries. 2021, 5:899-905. 10.24911/IJMDC.51-1611831096
- 23. Goh GB, Kwan C, Lim SY, et al.: Perceptions of non-alcoholic fatty liver disease an Asian community-based study. Gastroenterol Rep (Oxf). 2016, 4:131-5. 10.1093/gastro/gov047
- Tan CK, Goh GB, Youn J, Yu JC, Singh S: Public awareness and knowledge of liver health and diseases in Singapore. J Gastroenterol Hepatol. 2021, 36:2292-302. 10.1111/jgh.15496
- Lee HW, Kim M, Youn J, Singh S, Ahn SH: Liver diseases in South Korea: a pulse check of the public's knowledge, awareness, and behaviors. Yonsei Med J. 2022, 63:1088-98. 10.3349/ymj.2022.0332